David J Gottlieb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/386293/publications.pdf

Version: 2024-02-01

157	3,925	117571	149623
papers	citations	34 h-index	56 g-index

161	161	161	5043
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of donor age on adult unrelated donor haemopoietic cell transplant outcome: the Australian experience. Internal Medicine Journal, 2022, 52, 57-62.	0.5	0
2	Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: a cross-sectional survey. Journal of Cancer Survivorship, 2022, 16, 432-444.	1.5	3
3	Characterizing piggyBatâ€"a transposase for genetic modification of TÂcells. Molecular Therapy - Methods and Clinical Development, 2022, 25, 250-263.	1.8	4
4	Left atrial strain in cardiac surveillance of bone marrow transplant patients with prior anthracycline exposure. International Journal of Cardiology, 2022, 354, 68-74.	0.8	3
5	Zanubrutinib for treatmentâ€¤naÃ¯ve and relapsed/refractory chronic lymphocytic leukaemia: longâ€term followâ€up of the phase I/II AUâ€003 study. British Journal of Haematology, 2022, 196, 1209-1218.	1.2	24
6	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplantation, 2022, 57, 982-989.	1.3	3
7	Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation. Nature Communications, 2022, 13, 2603.	5.8	8
8	Combining <scp>CD34</scp> + stem cell selection with prophylactic pathogen and leukemia directed Tâ€cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant. American Journal of Hematology, 2022, , .	2.0	1
9	Donor-derived T cells specific for tumor antigen and multiple pathogens for prevention of relapse and infection after haemopoietic stem cell transplant (HSCT) for myeloid malignancies (the INTACT) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	
10	Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Advances, 2022, 6, 4949-4966.	2.5	16
11	Experiences and unmet needs of family members requested to donate haematopoietic stem cells to an ill relative: findings from a prospective multi-centre study. Supportive Care in Cancer, 2021, 29, 635-644.	1.0	3
12	Successful treatment of CMV, EBV, and adenovirus tissue infection following HLAâ€mismatched allogeneic stem cell transplant using infusion of thirdâ€party T cells from multiple donors in addition to antivirals, rituximab, and surgery. Transplant Infectious Disease, 2021, 23, e13528.	0.7	6
13	Intraocular solitary extramedullary plasmacytoma presenting as unilateral anterior and intermediate uveitis preceded by refractory glaucoma. BMC Ophthalmology, 2021, 21, 66.	0.6	0
14	Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. Journal of Psychosocial Oncology, 2021, 39, 534-552.	0.6	7
15	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. Journal of Virology, 2021, 95, .	1.5	48
16	A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood, 2021, 137, 1970-1979.	0.6	32
17	Combined chronic myeloid leukaemia and chronic lymphocytic leukaemia in five patients, including one with 17p deletion. Internal Medicine Journal, 2021, 51, 580-584.	0.5	0
18	Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells. Blood, 2021, 138, 1504-1509.	0.6	86

#	Article	IF	Citations
19	Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood, 2021, 138, 1391-1405.	0.6	87
20	The utility of strain imaging in the cardiac surveillance of bone marrow transplant patients. Heart, 2021, , heartjnl-2021-319359.	1.2	2
21	Australia and New Zealand Transplant and Cellular Therapies <scp>COVIDâ€19</scp> vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.5	6
22	Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transplantation and Cellular Therapy, 2021, 27, 1022.e1-1022.e6.	0.6	11
23	A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias. Blood, 2021, 138, 1595-1595.	0.6	0
24	Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. Blood, 2021, 138, 2929-2929.	0.6	0
25	Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. Blood, 2021, 138, 255-255.	0.6	0
26	Third-Party Partially HLA Matched Fungus-Specific T-Cells (FSTs) Used to Treat Invasive Fungal Infection (IFI) with Scedosporium Aurantiacum after Allogeneic Hemopoietic Stem Cell Transplant (aHSCT). Blood, 2021, 138, 2825-2825.	0.6	2
27	New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. Internal Medicine Journal, 2020, 50, 277-284.	0.5	12
28	Preâ€•and postâ€bone marrow harvest anaemia is associated with lower CD34+ stem cell collection, high harvest volume and female gender. Internal Medicine Journal, 2020, 50, 299-306.	0.5	1
29	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Biology of Blood and Marrow Transplantation, 2020, 26, 2252-2261.	2.0	6
30	Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Advances, 2020, 4, 4147-4150.	2.5	31
31	Fear of cancer recurrence following allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancy: A cross-sectional study. European Journal of Oncology Nursing, 2020, 49, 101845.	0.9	12
32	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	0.6	78
33	Rapidly expanded partially HLA DRB1â€“matched fungus-specific T cells mediate in vitro and in vivo antifungal activity. Blood Advances, 2020, 4, 3443-3456.	2.5	12
34	Ex vivo enrichment of PRAME antigenâ€specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clinical and Translational Immunology, 2020, 9, e1200.	1.7	8
35	Introducing 1,3â€Betaâ€Dâ€glucan for screening and diagnosis of invasive fungal diseases in Australian high risk haematology patients: is there a clinical benefit?. Internal Medicine Journal, 2020, , .	0.5	7
36	Bone Marrow Transplant Society of Australia and New Zealand COVIDâ€19 consensus position statement. Internal Medicine Journal, 2020, 50, 774-775.	0.5	3

#	Article	IF	Citations
37	Whole-Genome Approach to Assessing Human Cytomegalovirus Dynamics in Transplant Patients Undergoing Antiviral Therapy. Frontiers in Cellular and Infection Microbiology, 2020, 10, 267.	1.8	17
38	Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1711-1718.	2.0	9
39	Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMVâ€specific T cells. Clinical and Translational Immunology, 2020, 9, e1149.	1.7	18
40	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. Biology of Blood and Marrow Transplantation, 2020, 26, 1868-1875.	2.0	8
41	CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions. Molecular Therapy - Methods and Clinical Development, 2020, 17, 359-368.	1.8	22
42	Profiling the Blood Compartment of Hematopoietic Stem Cell Transplant Patients During Human Cytomegalovirus Reactivation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 607470.	1.8	4
43	Three-year follow-up of treatment-naÃ¯ve and previously treated patients with WaldenstrÃ¶m macroglobulinemia (WM) receiving single-agent zanubrutinib.. Journal of Clinical Oncology, 2020, 38, 8051-8051.	0.8	5
44	Single cell analysis reveals human cytomegalovirus drives latently infected cells towards an anergic-like monocyte state. ELife, 2020, 9, .	2.8	46
45	An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation. Blood, 2020, 136, 36-37.	0.6	1
46	A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up. Blood, 2020, 136, 51-52.	0.6	0
47	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 18-19.	0.6	0
48	Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 7-8.	0.6	0
49	Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 25-26.	0.6	1
50	Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial). Blood, 2020, 136, 38-38.	0.6	0
51	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	0.6	259
52	Postâ€allogeneic transplant Evans syndrome successfully treated with daratumumab. British Journal of Haematology, 2019, 187, e48-e51.	1.2	27
53	Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Frontiers in Microbiology, 2019, 10, 1186.	1.5	105
54	Adult related haematopoietic stem cell donor care: Views of Transplant Nurses. European Journal of Oncology Nursing, 2019, 41, 56-63.	0.9	2

#	Article	IF	Citations
55	Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding. Scientific Reports, 2019, 9, 3214.	1.6	40
56	Adoptive cell therapies for posttransplant infections. Current Opinion in Oncology, 2019, 31, 574-590.	1.1	12
57	A survey of infectious diseases and vaccination uptake in longâ€term hematopoietic stem cell transplant survivors in Australia. Transplant Infectious Disease, 2019, 21, e13043.	0.7	14
58	Restriction of Human Cytomegalovirus Infection by Galectin-9. Journal of Virology, 2019, 93, .	1.5	18
59	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood, 2019, 134, 500-500.	0.6	18
60	Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 368-368.	0.6	7
61	Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). Blood, 2019, 134, 251-251.	0.6	3
62	An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era. Blood, 2019, 134, 5719-5719.	0.6	0
63	Changes to work status and household income of long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia. Bone Marrow Transplantation, 2018, 53, 926-931.	1.3	6
64	Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies. Biology of Blood and Marrow Transplantation, 2018, 24, 1069-1078.	2.0	36
65	Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. Biology of Blood and Marrow Transplantation, 2018, 24, 169-174.	2.0	4
66	Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 71-77.	2.0	13
67	Staff influenza vaccination rate in three major blood and marrow transplant units in New South Wales: room for improvement. Internal Medicine Journal, 2018, 48, 1277-1278.	0.5	0
68	Anncaliia algerae Microsporidial Myositis, New South Wales, Australia. Emerging Infectious Diseases, 2018, 24, 1528-1531.	2.0	16
69	Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program. Biology of Blood and Marrow Transplantation, 2018, 24, 2433-2442.	2.0	50
70	PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts. Molecular Therapy, 2018, 26, 1883-1895.	3.7	43
71	Oral health and dental morbidity in longâ€term allogeneic blood and marrow transplant survivors in Australia. Australian Dental Journal, 2018, 63, 312-319.	0.6	12
72	Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a singleâ€centre case series. Internal Medicine Journal, 2018, 48, 988-991.	0.5	5

#	Article	IF	Citations
73	Combined CML and CLL in four patients, including one with 17p deletion. Pathology, 2018, 50, S101-S102.	0.3	1
74	Abstract 3572: CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma. , 2018, , .		0
75	Co-Administration of 3rdparty Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation. Blood, 2018, 132, 2051-2051.	0.6	0
76	Clinically significant recurrent copy number changes detected by chromosome microarray in the CHW multiple myeloma patient cohort. Pathology, 2017, 49, S31.	0.3	0
77	Prospects for adoptive T-cell therapy for invasive fungal disease. Current Opinion in Infectious Diseases, 2017, 30, 518-527.	1.3	17
78	Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant. Cytotherapy, 2017, 19, 1284-1301.	0.3	17
79	Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy. Cytotherapy, 2017, 19, 107-118.	0.3	14
80	Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?. Supportive Care in Cancer, 2017, 25, 421-427.	1.0	23
81	Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Advances, 2017, 1, 2193-2205.	2.5	115
82	Abstract 3760: Preclinical optimization of a low cost PiggyBac transposase (PB) generated CD19-specific chimeric antigen receptor T cell (CART19) product for a first in man trial using local hospital cell manufacture. , 2017, , .		0
83	Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. Cancer Medicine, 2016, 5, 3606-3614.	1.3	9
84	Transient acantholytic dyskeratosis (Grover's disease) after bone marrow transplantation. Australasian Journal of Dermatology, 2016, 57, e120-e122.	0.4	4
85	Third-Party Virus-Specific T Cells (VST) Are Efficacious in the Treatment of Refractory Infection Post-HSCT, However Other Cell-Mediated Immune Deficiencies Appear to Persist. Biology of Blood and Marrow Transplantation, 2016, 22, S147.	2.0	1
86	The experience of survival following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia. Bone Marrow Transplantation, 2016, 51, 1361-1368.	1.3	18
87	Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (<scp>BMT</scp>). Cancer Medicine, 2016, 5, 1702-1716.	1.3	15
88	CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence, 2016, 7, 967-980.	1.8	45
89	Stimulation with lysates of Aspergillus terreus, Candida krusei and Rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. Cytotherapy, 2016, 18, 65-79.	0.3	18
90	The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 2016, 183, 206-220.	1.1	38

#	Article	IF	Citations
91	Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Blood, 2016, 128, 2053-2053.	0.6	3
92	Infusion of Unrelated-Donor Partially HLA-Matched Cells Results in Detectable Microchimerism in Patients with Acute Myeloid Leukemia: Early Post-Infusion Reactions Are Common but Self-Limiting. Blood, 2016, 128, 3405-3405.	0.6	1
93	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 642-642.	0.6	23
94	Pulmonary function changes following allogeneic haematopoietic cell transplantation. , 2016, , .		0
95	Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. Blood, 2016, 128, 939-939.	0.6	0
96	Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigenâ€“Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 941-944.	2.0	48
97	HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 2015, 32, 126-130.	0.6	10
98	Low-cost generation of Good Manufacturing Practiceâ€“grade CD19-specific chimeric antigen receptorâ€“expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy, 2015, 17, 1251-1267.	0.3	75
99	Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants UsingÂHaploidentical Related Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 1641-1645.	2.0	38
100	Adoptive T-cell therapy for fungal infections in haematology patients. Clinical and Translational Immunology, 2015, 4, e40.	1.7	23
101	Addition of varicella zoster virusâ€“specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2015, 17, 1406-1420.	0.3	53
102	Antifungal T cellsâ€”progress in manufacture and prospects for the clinic. Cytotherapy, 2015, 17, 1329-1331.	0.3	4
103	A fatal case of acute HHV-6 myocarditis following allogeneic haemopoietic stem cell transplantation. Journal of Clinical Virology, 2015, 72, 82-84.	1.6	5
104	Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion. Blood, 2015, 126, 623-623.	0.6	6
105	A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944â€“2013). Seminars in Thrombosis and Hemostasis, 2014, 40, 001-004.	1.5	0
106	Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients. Internal Medicine Journal, 2014, 44, 1038-1040.	0.5	1
107	Human Cytomegalovirus Upregulates Expression of the Lectin Galectin 9 via Induction of Beta Interferon. Journal of Virology, 2014, 88, 10990-10994.	1.5	23
108	An Unusual Cause of Cerebellar Hemorrhage in a Young Patient: Essential Thrombocythemia. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e373-e374.	0.7	9

#	Article	IF	Citations
109	Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection. Blood, 2014, 124, 3835-3835.	0.6	0
110	Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factorâ€"Mobilized Hemopoietic Progenitor Cell Products ExÂVivo and Safely Transferred to Stem Cell Transplantation Recipients to Facilitate Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2013, 19, 725-734.	2.0	34
111	Reduced Intensity Transplants Using G-CSF-Mobilized Hemopoietic Cells From Haploidentical Related Donors. Biology of Blood and Marrow Transplantation, 2013, 19, S283.	2.0	2
112	Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood, 2013, 121, 3745-3758.	0.6	219
113	Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies. Biology of Blood and Marrow Transplantation, 2013, 19, 1046-1058.	2.0	46
114	Human Cytomegalovirus Interleukin-10 Polarizes Monocytes toward a Deactivated M2c Phenotype To Repress Host Immune Responses. Journal of Virology, 2013, 87, 10273-10282.	1.5	71
115	Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research, 2013, 19, 731-742.	3.2	91
116	In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy. Cytotherapy, 2012, 14, 182-193.	0.3	16
117	Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients. Cytotherapy, 2012, 14, 724-732.	0.3	24
118	Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy, 2012, 14, 1119-1130.	0.3	29
119	A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies lowâ€, intermediateâ€, and highâ€risk groups: reactivation risk is increased by graftâ€versusâ€host disease only in the intermediateâ€risk group. Transplant Infectious Disease, 2012, 14, 141-148.	0.7	48
120	Tumorâ€specific but not nonspecific cellâ€free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematology, 2012, 87, 258-265.	2.0	30
121	The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2011, 17, 147-153.	2.0	28
122	Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology, 2011, 43, 605-615.	0.3	4
123	BK Virus-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses. Transplantation, 2011, 92, 1077-1084.	0.5	61
124	Mobilisation strategies for normal and malignant cells. Pathology, 2011, 43, 547-565.	0.3	8
125	T time for transplants. Blood, 2010, 116, 4391-4393.	0.6	1
126	Manufacturing of human placentaâ€derived mesenchymal stem cells for clinical trials. British Journal of Haematology, 2009, 144, 571-579.	1.2	145

#	Article	IF	Citations
127	Endoscopic ultrasoundâ€fine needle aspiration for the diagnosis of lymphoma: Are we there yet?. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1808-1809.	1.4	4
128	Failure to Achieve a Threshold Dose of CD34+CD110+ Progenitor Cells in the Graft Predicts Delayed Platelet Engraftment after Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 1386-1393.	2.0	17
129	Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity. Cytotherapy, 2009, 11, 218-228.	0.3	5
130	The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood, 2009, 114, 4128-4137.	0.6	84
131	Factors Predicting the Outcome of the Blood and Marrow Transplant Patients Admitted to Intensive Care Unit.. Blood, 2009, 114, 3340-3340.	0.6	0
132	Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood, 2008, 112, 3974-3981.	0.6	108
133	Use of Reduced Intensity Conditioning (RIC) Regimens Are Associated with a Better Outcome with Sibling Donors Transplants in Older Patients (> 50 years) with Acute Myeloid Leukemia (AML). Blood, 2008, 112, 3307-3307.	0.6	1
134	Ex Vivo Expansion and Prophylactic Infusion of CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 707-714.	2.0	122
135	Ex-Vivo Expansion and Prophylactic Infusion of CMV pp65 Specific CTL Following Haemopoietic Stem Cell Transplantation (HSCT).. Blood, 2005, 106, 3244-3244.	0.6	0
136	Absolute Number of Transplanted CD34+ Cells Expressing c-mpl (CD110) Correlates with Speed of Platelet Engraftment Following Autologous Stem Cell Transplantation.. Blood, 2005, 106, 1078-1078.	0.6	0
137	Ex-Vivo Uses and Applications of Cytokines for Adoptive Immunotherapy in Cancer. Current Pharmaceutical Design, 2004, 10, 1207-1220.	0.9	10
138	Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture. Biotechnology and Bioengineering, 2004, 85, 138-146.	1.7	22
139	A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2â^' donors. Biology of Blood and Marrow Transplantation, 2004, 10, 761-771.	2.0	15
140	Bilateral Leukemic Orbital Infiltration Presenting as Proptosis and Narrow-Angle Glaucoma. Ophthalmic Plastic and Reconstructive Surgery, 2004, 20, 248-250.	0.4	11
141	Human CD62Lâ€“ memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood, 2004, 104, 2403-2409.	0.6	101
142	A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunology and Cell Biology, 2003, 81, 311-319.	1.0	4
143	Rapid, Large-Scale Generation of Highly Pure Cytomegalovirus-Specific Cytotoxic T Cells for Adoptive Immunotherapy. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 93-105.	1.8	18
144	Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia. Current Pharmaceutical Design, 2002, 8, 419-431.	0.9	8

#	Article	IF	Citations
145	Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 501-511.	2.0	40
146	The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Experimental Hematology, 2001, 29, 1439-1447.	0.2	122
147	Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Research and Treatment, 2000, 63, 105-115.	1.1	45
148	VLA-4 is involved in the engraftment of the human pre-B acute lymphoblastic leukaemia cell line NALM-6 in SCID mice. British Journal of Haematology, 1998, 102, 1292-1300.	1.2	27
149	Antileukemic Effects of Rapid Cyclosporin Withdrawal in Patients with Relapsed Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation. Leukemia and Lymphoma, 1998, 31, 545-550.	0.6	20
150	A second case of hexasomy 8 in myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 1997, 99, 68-72.	1.0	4
151	Antibodies to CD44 enhance adhesion of normal CD34+cells and acute myeloblastic but not lymphoblastic leukaemia cells to bone marrow stroma. British Journal of Haematology, 1997, 98, 828-837.	1.2	14
152	Ultrastructural changes during adhesion and migration of pre-B lymphoid leukaemia cells within bone marrow stroma. British Journal of Haematology, 1996, 92, 77-87.	1.2	12
153	Interaction of Acute Leukemia Cells with the Bone Marrow Microenvironment: Implications for Control of Minimal Residual Disease. Leukemia and Lymphoma, 1995, 18, 1-16.	0.6	102
154	Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. British Journal of Haematology, 1991, 77, 237-244.	1.2	38
155	Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. British Journal of Haematology, 1990, 75, 499-505.	1.2	30
156	Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. British Journal of Haematology, 1989, 72, 122-126.	1.2	22
157	The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer, 1987, 60, 1439-1441.	2.0	61